<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2014.3009</article-id>
<article-id pub-id-type="publisher-id">or-31-04-1729</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Curcumin synergistically enhances the radiosensitivity of human oral squamous cell carcinoma via suppression of radiation-induced NF-&#x003BA;B activity</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>CHIANG</surname><given-names>I-TSANG</given-names></name><xref rid="af1-or-31-04-1729" ref-type="aff">1</xref><xref rid="fn1-or-31-04-1729" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>LIU</surname><given-names>YU-CHANG</given-names></name><xref rid="af1-or-31-04-1729" ref-type="aff">1</xref><xref rid="af2-or-31-04-1729" ref-type="aff">2</xref><xref rid="fn1-or-31-04-1729" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>HSU</surname><given-names>FEI-TING</given-names></name><xref rid="af1-or-31-04-1729" ref-type="aff">1</xref><xref rid="fn1-or-31-04-1729" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>CHIEN</surname><given-names>YI-CHUN</given-names></name><xref rid="af1-or-31-04-1729" ref-type="aff">1</xref><xref rid="af3-or-31-04-1729" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>KAO</surname><given-names>CHIH-HAO K.</given-names></name><xref rid="af4-or-31-04-1729" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author">
<name><surname>LIN</surname><given-names>WUU-JYH</given-names></name><xref rid="af5-or-31-04-1729" ref-type="aff">5</xref></contrib>
<contrib contrib-type="author">
<name><surname>CHUNG</surname><given-names>JING-GUNG</given-names></name><xref rid="af6-or-31-04-1729" ref-type="aff">6</xref></contrib>
<contrib contrib-type="author">
<name><surname>HWANG</surname><given-names>JENG-JONG</given-names></name><xref rid="af1-or-31-04-1729" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-or-31-04-1729"/></contrib></contrib-group>
<aff id="af1-or-31-04-1729">
<label>1</label>Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan, R.O.C.</aff>
<aff id="af2-or-31-04-1729">
<label>2</label>Department of Radiation Oncology, National Yang-Ming University Hospital, Yilan, Taiwan, R.O.C.</aff>
<aff id="af3-or-31-04-1729">
<label>3</label>Department of Medical Imaging and Radiological Sciences, I-Shou University, Kaohsiung, Taiwan, R.O.C.</aff>
<aff id="af4-or-31-04-1729">
<label>4</label>Department of Radiopharmaceutical Production, Hualien Tzu Chi Hospital, Hualien, Taiwan, R.O.C.</aff>
<aff id="af5-or-31-04-1729">
<label>5</label>Division of Radioisotope, Institute of Nuclear Energy Research, Taoyuan, Taiwan, R.O.C.</aff>
<aff id="af6-or-31-04-1729">
<label>6</label>Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.</aff>
<author-notes>
<corresp id="c1-or-31-04-1729">Correspondence to: Professor Jeng-Jong Hwang, Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Bei-tou, Taipei 112, Taiwan, R.O.C., E-mail: <email>jjhwang@ym.edu.tw</email></corresp><fn id="fn1-or-31-04-1729">
<label>&#x0002A;</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>4</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>01</month>
<year>2014</year></pub-date>
<volume>31</volume>
<issue>4</issue>
<fpage>1729</fpage>
<lpage>1737</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>09</month>
<year>2013</year></date>
<date date-type="accepted">
<day>11</day>
<month>11</month>
<year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>The anticancer effect of curcumin has been widely reported. However, whether curcumin can enhance the radiosensitivity of human oral squamous cell carcinoma (OSCC) remains to be elucidated. The aim of the present study was to evaluate the efficacy of curcumin combined with radiation against OSCC. SAS cells were transfected with the luciferase gene (<italic>luc</italic>) and named SAS/<italic>luc</italic>. NF-&#x003BA;B/DNA binding activity, the surviving fraction and NF-&#x003BA;B-regulated effector protein expression were determined by electrophoretic mobility shift assay, clonogenic survival assay and western blotting, respectively. The therapeutic efficacy was evaluated in SAS/<italic>luc</italic> tumor-bearing mice by caliper measurement and bioluminescence imaging. Curcumin enhanced SAS/<italic>luc</italic> radiosensitivity through the inhibition of radiation-induced NF-&#x003BA;B activity and expression of effector proteins both <italic>in vitro</italic> and <italic>in vivo</italic>. With 4 Gy or greater radiation doses, synergistic effects of curcumin were observed. The combination group (curcumin plus radiation) had significantly better tumor control compared with that of curcumin or radiation alone. No significant body weight change of mice was found throughout the entire study. In conclusion, curcumin is a radiosensitizer against OSCC with negligible toxicity.</p></abstract>
<kwd-group>
<kwd>curcumin</kwd>
<kwd>radiotherapy</kwd>
<kwd>nuclear factor-&#x003BA;B</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Oral squamous cell carcinoma (OSCC) is the most common head and neck cancer in Taiwan. Radiotherapy plays a major role in the postoperative or definitive treatment for patients with locoregionally advanced disease. Unfortunately, more than half of high-risk patients develop locoregional recurrence and/or distant metastasis despite aggressive treatment (<xref rid="b1-or-31-04-1729" ref-type="bibr">1</xref>). Radioresistance has been described in the literature to be related to several signaling pathways, such as cyclooxygenase-2 (COX-2), matrix metalloproteinase-9 (MMP-9), tumor necrosis factor-&#x003B1; (TNF-&#x003B1;) and hypoxia-inducible factor-&#x003B1; (HIF-&#x003B1;) (<xref rid="b2-or-31-04-1729" ref-type="bibr">2</xref>&#x02013;<xref rid="b4-or-31-04-1729" ref-type="bibr">4</xref>). Nuclear factor-&#x003BA;B (NF-&#x003BA;B) is the key molecule for relaying signals from these pathways to express downstream effectors, which are responsible for radioresistance (<xref rid="b2-or-31-04-1729" ref-type="bibr">2</xref>).</p>
<p>Irradiation is able to activate NF-&#x003BA;B and subsequent transcription of effector proteins governing cell proliferation (such as cyclin D1), angiogenesis &#x0005B;such as vascular endothelial growth factor (VEGF)&#x0005D;, invasion (such as MMP-9), and anti-apoptosis &#x0005B;such as B-cell lymphoma 2 protein (BCL-2), x-linked inhibitor of apoptosis protein (XIAP) and cellular FLICE-like inhibitory protein (C-FLIP)&#x0005D;, resulting in radioresistance and poorer treatment outcome (<xref rid="b5-or-31-04-1729" ref-type="bibr">5</xref>,<xref rid="b6-or-31-04-1729" ref-type="bibr">6</xref>). These NF-&#x003BA;B-regulated effectors (i.e. cyclin D1, VEGF, MMP-9, BCL-2 and XIAP) have been suggested to be biomarkers indicating cancer treatment resistance in OSCC (<xref rid="b7-or-31-04-1729" ref-type="bibr">7</xref>&#x02013;<xref rid="b10-or-31-04-1729" ref-type="bibr">10</xref>).</p>
<p>Inhibition of the NF-&#x003BA;B signaling cascade increases cancer cell sensitivity to radiotherapy and chemotherapy (<xref rid="b11-or-31-04-1729" ref-type="bibr">11</xref>,<xref rid="b12-or-31-04-1729" ref-type="bibr">12</xref>). In addition, tumor infiltrating inflammatory and stromal cells in the microenvironment promote prosurvival and oncogenic signals through activation of NF-&#x003BA;B, which appears to be an appropriate target for cancer therapy from the aspect of reversing therapeutic resistance (<xref rid="b6-or-31-04-1729" ref-type="bibr">6</xref>).</p>
<p>In comparison with radiotherapy alone, combined chemotherapy and radiotherapy (CCRT) simultaneously could enhance locoregional control and disease-free survival in patients with high-risk head and neck cancer. However, acute severe toxicity occurs more frequently in patients receiving CCRT and may affect treatment compliance and even result in treatment-related death (<xref rid="b13-or-31-04-1729" ref-type="bibr">13</xref>). An ideal radiosensitizer should enhance the radiosensitivity of cancer cells to achieve better tumor control without increasing normal tissue toxicity. Curcumin, commonly known as the spice turmeric, is a polyphenol derived from the plant <italic>Curcuma longa</italic>, and has been shown to have anticancer, antioxidant and anti-inflammatory effects (<xref rid="b14-or-31-04-1729" ref-type="bibr">14</xref>). When embedded with liposome and administered intravenously, curcumin is able to reduce radiation-induced lung damage (<xref rid="b15-or-31-04-1729" ref-type="bibr">15</xref>). Treating OSCC with curcumin was found to result in growth inhibition through suppression of NF-&#x003BA;B (<xref rid="b16-or-31-04-1729" ref-type="bibr">16</xref>). Radiation combined with curcumin was found to have an additive effect on head and neck squamous cell carcinoma possibly through inhibition of epidermal growth factor receptor (EGFR) phosphorylation and COX-2 expression (<xref rid="b17-or-31-04-1729" ref-type="bibr">17</xref>). Nevertheless, whether curcumin can sensitize OSCC to radiation via suppression of NF-&#x003BA;B activation has not yet been elucidated. In the present study, we used molecular imaging to evaluate the therapeutic efficacy of curcumin combined with radiation on luciferase reporter gene (<italic>luc</italic>)-carrying OSCC cell line (SAS/<italic>luc</italic>) tumor-bearing mice. The effect of curcumin on radiation-induced NF-&#x003BA;B activity and NF-&#x003BA;B-regulated products in SAS/<italic>luc</italic> cells was also investigated. In order to verify the role of NF-&#x003BA;B inhibition, SAS cells were transfected with NF-&#x003BA;B super-repressor (p-I&#x003BA;B&#x003B1;M). The combined effects of p-I&#x003BA;B&#x003B1;M transfection and radiation on SAS cells were studied.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Experimental design</title>
<p>The <italic>in vitro</italic> and <italic>in vivo</italic> studies were divided into two parts. The first part was to investigate whether curcumin has a radiosensitizing effect and the experiments were subdivided into four groups: the control group (control or vehicle), curcumin-treated group (curcumin alone), radiation-treated group (radiation alone) and combined treatment group (combination). The other part was to verify the effect of the I&#x003BA;B&#x003B1;M vector, which represses constitutive or radiation-induced NF-&#x003BA;B activity, to radiosensitize the OSCC cell line. This experiment was also subdivided into four groups: empty vector-transfected group (empty vector), p-I&#x003BA;B&#x003B1;M-transfected group (I&#x003BA;B&#x003B1;M vector), radiation-treated group (radiation alone) and p-I&#x003BA;B&#x003B1;M-transfection plus radiation group (combination). The Experimental Animal Care and Use Committee of the National Yang-Ming University Office of Research and Development approved the experiment.</p></sec>
<sec>
<title>Plasmid transfection and stable clone selection</title>
<p>Stable clones of SAS/<italic>luc</italic> cells were established as described in our previous study (<xref rid="b18-or-31-04-1729" ref-type="bibr">18</xref>). In brief, SAS cells were transfected with the pC1-<italic>luc</italic> vector using jetPEI&#x02122; (Polyplus Transfection, S&#x000E9;lestat, France). Cells (2&#x000D7;10<sup>5</sup>) were seeded in a 100-mm diameter dish containing 3 ml Dulbecco&#x02019;s modified essential medium (DMEM; Gibco-Life Technologies, Grand Island, NY, USA) 24 h before transfection. pC1-<italic>luc</italic> (5 &#x003BC;l) and 10 &#x003BC;l of jetPEI<sup>TM</sup> solution were diluted in 500 &#x003BC;l of 150 mM NaCl, respectively, then mixed together and incubated for 30 min at 37&#x000B0;C. The jetPEI/plasmid vector mixture was added to SAS cells and incubated at 37&#x000B0;C for another 24 h. Cells were then trypsinized and cultured in 100-mm dishes with DMEM containing 1 mg/ml G418 (Merck, Darmstadt, Germany) supplemented with 10&#x00025; fetal bovine serum (FBS; Biological Industries, Beit Haemek, Israel) for 2 weeks. The surviving clones were isolated and transferred to 96-well plates for growth. The Luc protein expression in each clone was assayed using BLI. The recombinant bioluminescent cell clone was named SAS/<italic>luc</italic>.</p>
<p>The I&#x003BA;B&#x003B1; mutant vector (p-I&#x003BA;B&#x003B1;M; Clontech, Mountain View, CA, USA) was used to transfect SAS cells using the same protocol as in our previous study (<xref rid="b19-or-31-04-1729" ref-type="bibr">19</xref>). The inhibitory effect of p-I&#x003BA;B&#x003B1;M super repressor on NF-&#x003BA;B activation was confirmed with electrophoretic mobility shift assay (EMSA). p-I&#x003BA;B&#x003B1;M-transfected SAS cells were used as a negative control of NF-&#x003BA;B activation.</p></sec>
<sec>
<title>Cell culture</title>
<p>SAS/<italic>luc</italic> cells were cultured in DMEM supplemented with 10&#x00025; FBS and 100 U/ml penicillin plus 100 &#x003BC;g/ml streptomycin (Gibco-Life Technologies) at 37&#x000B0;C in a humidified atmosphere of 5&#x00025; CO<sub>2</sub>. G418 (500 &#x003BC;g/ml) was added to the medium to maintain the stable expression of the <italic>luc</italic> gene.</p></sec>
<sec>
<title>Cytotoxicity of curcumin</title>
<p>SAS/<italic>luc</italic> cells were seeded in 96-well plates (3,000 cells/well), incubated for 24 h, and then treated with different concentrations (0&#x02013;50 &#x003BC;M) of curcumin (Sigma-Aldrich, St. Louis, MO, USA) for another 24 or 48 h. Cells were then washed with fresh medium. Subsequently, 100 &#x003BC;l of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) solution was added into each well and incubated for 4 h at 37&#x000B0;C. After removing the MTT solution, cells were exposed to 100 &#x003BC;l of dimethyl sulfoxide for 5 min, and plates were scanned with an enzyme-linked immunosorbent assay (ELISA) reader (PowerWave X340; BioTek, Winooski, VT, USA) using a test wavelength of 570 nm and a reference wavelength of 630 nm.</p></sec>
<sec>
<title>Clonogenic survival assay</title>
<p>SAS/<italic>luc</italic> cells (1&#x000D7;10<sup>6</sup>) were seeded in 100-mm dishes (2 dishes per group), incubated for 24 h, and then treated with or without 30 &#x003BC;M curcumin (i.e. half maximal inhibitory concentration, IC<sub>50</sub>). Cells were irradiated immediately with various doses (2&#x02013;12 Gy) using an X-ray irradiator (RS 2000; Rad Source Technologies, Suwanee, GA, USA) at a dose rate of 1.03 Gy/min, 80 cm source-to-skin distance (SSD) and field size of 30&#x000D7;30 cm<sup>2</sup>. After irradiation, cells were incubated for 24 h. After that, cells were trypsinized, washed and resuspended in fresh medium, and then seeded in 100-mm diameter dishes. Twelve days later, the cell colonies were fixed with methanol:acetic acid (3:1) solution and stained with 2&#x00025; crystal violet. The cell colony was deemed surviving when there were &gt;50 cells. The surviving fraction (SF) was defined as the ratio of surviving colonies to the number of plated cells with correction for plating efficiency. The radiosensitization effect of curcumin on SAS/<italic>luc</italic> cells was evaluated according to the formulas (as listed below) suggested by Valeriote and Lin (<xref rid="b20-or-31-04-1729" ref-type="bibr">20</xref>) and Carpentier <italic>et al</italic> (<xref rid="b21-or-31-04-1729" ref-type="bibr">21</xref>).</p>
<disp-formula id="fd1-or-31-04-1729">
<mml:math id="m1" display='block'>
<mml:semantics id="sm1">
<mml:mtable columnalign='left'>
<mml:mtr>
<mml:mtd>
<mml:mtext>Synergism</mml:mtext>
<mml:mo>&#x002C;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mrow>
<mml:mtext>R</mml:mtext>
<mml:mo>&#x002B;</mml:mo>
<mml:mtext>C</mml:mtext></mml:mrow></mml:msub>
<mml:mo>&lt;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>R</mml:mtext></mml:msub>
<mml:mo>&#x000D7;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>C</mml:mtext></mml:msub>
<mml:mo>&#x003B;</mml:mo></mml:mtd></mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>Additivity</mml:mtext>
<mml:mo>&#x002C;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mrow>
<mml:mtext>R</mml:mtext>
<mml:mo>&#x002B;</mml:mo>
<mml:mtext>C</mml:mtext></mml:mrow></mml:msub>
<mml:mo>&#x003D;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>R</mml:mtext></mml:msub>
<mml:mo>&#x000D7;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>C</mml:mtext></mml:msub>
<mml:mo>&#x003B;</mml:mo></mml:mtd></mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mtext>Sub</mml:mtext>
<mml:mo>&#x002D;</mml:mo>
<mml:mtext>additivity</mml:mtext></mml:mrow>
<mml:mo>&#x002C;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mrow>
<mml:mtext>R</mml:mtext>
<mml:mo>&#x002B;</mml:mo>
<mml:mtext>C</mml:mtext></mml:mrow></mml:msub>
<mml:mo>&gt;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>R</mml:mtext></mml:msub>
<mml:mo>&#x000D7;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>C</mml:mtext></mml:msub>
<mml:mo>&#x002C;</mml:mo>
<mml:mi>&#x02009;</mml:mi>
<mml:mtext>with&#x02009;</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mrow>
<mml:mtext>R</mml:mtext>
<mml:mo>&#x002B;</mml:mo>
<mml:mtext>C</mml:mtext></mml:mrow></mml:msub>
<mml:mo>&lt;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>R</mml:mtext></mml:msub>
<mml:mi>&#x02009;</mml:mi>
<mml:mtext>and&#x02009;</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mrow>
<mml:mtext>R</mml:mtext>
<mml:mo>&#x002B;</mml:mo>
<mml:mtext>C</mml:mtext></mml:mrow></mml:msub>
<mml:mo>&lt;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>C</mml:mtext></mml:msub>
<mml:mo>&#x003B;</mml:mo></mml:mtd></mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>Antagonism</mml:mtext>
<mml:mo>&#x002C;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mrow>
<mml:mtext>R</mml:mtext>
<mml:mo>&#x002B;</mml:mo>
<mml:mtext>C</mml:mtext></mml:mrow></mml:msub>
<mml:mo>&gt;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>R</mml:mtext></mml:msub>
<mml:mi>&#x02009;</mml:mi>
<mml:mtext>and</mml:mtext>
<mml:mo>&#x002F;</mml:mo>
<mml:mtext>or&#x02009;</mml:mtext>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mrow>
<mml:mtext>R</mml:mtext>
<mml:mo>&#x002B;</mml:mo>
<mml:mtext>C</mml:mtext></mml:mrow></mml:msub>
<mml:mo>&gt;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>SF</mml:mtext></mml:mrow>
<mml:mtext>C</mml:mtext></mml:msub>
<mml:mo>&#x002C;</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:semantics></mml:math></disp-formula>
<p>where SF<sub>R</sub> is the surviving fraction of SAS/<italic>luc</italic> cells treated by radiation alone; SF<sub>C</sub> is the surviving fraction of SAS/<italic>luc</italic> cells treated with IC<sub>50</sub> curcumin alone (SF<sub>C</sub> &#x0003D; 0.5); SF<sub>R&#x0002B;C</sub> is the surviving fraction of SAS/<italic>luc</italic> cells treated by radiation plus IC<sub>50</sub> curcumin.</p>
<p>The surviving fraction of SAS/<italic>luc</italic> cells transfected with the empty or p-I&#x003BA;B&#x003B1;M vector was obtained using the same procedure as mentioned above.</p></sec>
<sec>
<title>Electrophoretic mobility shift assay (EMSA)</title>
<p>After treatment with 6 Gy irradiation, 30 &#x003BC;M curcumin for 24 h, or a combination of both, a nuclear extraction kit (Chemicon, EMD Millipore, Billerica, MA, USA) was used to isolate the nuclear fractions of SAS/<italic>luc</italic> cells. The protocol for NF-&#x003BA;B/DNA binding activity evaluation followed the instructions provided with the kit (LightShift Chemiluminescent EMSA kit; Thermo Scientific Pierce Protein Biology Products, Rockford, IL, USA). The following DNA sequences were synthesized for EMSA analysis: sense, AGTTGAGGGGACTTTCCCAGGC and antisense, GCCTGGGAAAGTCCCCTCAACT. Nuclear extracts were incubated with the biotin-labeled DNA probe for 20 min at room temperature. The DNA-protein complex was separated from the free oligonucleotides on a 5&#x00025; polyacrylamide gel, transferred to a nylon membrane and cross-linked by UV light. The membrane was incubated with streptavidin-horseradish peroxidase and detected by enhanced chemiluminescence (ECL; Thermo Scientific Pierce Protein Biology Products).</p></sec>
<sec>
<title>DNA fragmentation</title>
<p>SAS/<italic>luc</italic> cells (1&#x000D7;10<sup>6</sup>) were grown in 6-well plates and treated with 6 Gy irradiation, 30 &#x003BC;M curcumin for 24 h or a combination of both. After treatment, a genomic DNA purification kit (Axygen, Tewksbury, MA, USA) was used to extract fragmented DNA following the protocol provided by the manufacturer. DNA laddering was analyzed with 1.5&#x00025; agarose gel electrophoresis.</p></sec>
<sec>
<title>Western blotting</title>
<p>SAS/<italic>luc</italic> cells (2&#x000D7;10<sup>6</sup>) were seeded into 100-mm diameter dishes and treated with 30 &#x003BC;M curcumin, 6 Gy irradiation or a combination of both. The cells were then lysed with 100 &#x003BC;l lysis buffer (50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 0.5&#x00025; NP-40, 1 mM phenylmethanesulfonyl fluoride). Total proteins (40 &#x003BC;g) were separated by 10&#x00025; sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride membrane (EMD Millipore). The membranes were blocked with 5&#x00025; non-fat milk for 1 h, and probed with the appropriate primary antibody (VEGF, MMP-9, BCL-2, XIAP, C-FLIP, cleaved-caspase-3, caspase-8, cytochrome <italic>c</italic> and &#x003B2;-actin; EMD Millipore) overnight at 4&#x000B0;C. The membranes were then washed in Tris-Tween buffer saline and incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) at room temperature for 1 h. Final quantification was achieved by using an ECL detection system (EMD Millipore). A cytosol/nuclear extraction kit (Chemicon International, Temecula, CA, USA) was used to isolate cytosolic cytochrome <italic>c</italic> following the instructions provided with the kit (<xref rid="b22-or-31-04-1729" ref-type="bibr">22</xref>).</p></sec>
<sec>
<title>Tumor-bearing animal model</title>
<p>Six-week-old male NOD/SCID mice were purchased from the National Laboratory Animal Center, Taipei, Taiwan. SAS/<italic>luc</italic> cells (1&#x000D7;10<sup>6</sup>) in 0.2 ml serum-free medium were inoculated subcutaneously into the right legs of NOD/SCID mice. When the tumor volume reached 70 mm<sup>3</sup>, mice were randomized into four groups (n&#x0003D;5 for each group) according to the treatment modality: i) control group (phosphate-buffered solution with 1&#x00025; dimethyl sulfoxide by gavage daily); ii) curcumin alone group (70 mg/kg/day by gavage from day 1 for 3 weeks); iii) radiation alone group (single dose 6 Gy on day 1); and iv) combination group (70 mg/kg/day by gavage from day 1 for 3 weeks plus 6 Gy irradiation on day 1). The treatment protocol for mice is depicted in <xref rid="f4-or-31-04-1729" ref-type="fig">Fig. 4</xref>. Tumor volume was measured by caliper weekly and calculated by the following formula (<xref rid="b23-or-31-04-1729" ref-type="bibr">23</xref>): Volume &#x0003D; 1/2 &#x000D7; (4/3)&#x003C0; &#x000D7; length/2 &#x000D7; width/2 &#x000D7; thickness &#x0003D; 0.523 &#x000D7; (length &#x000D7; width &#x000D7; thickness).</p>
<p>The body weight of mice was monitored after treatment together with tumor volume tracking. Mice were sacrificed on day 21 for pathologic examination of the liver. All animal experiments complied with institutional animal care guidelines.</p></sec>
<sec>
<title>In vivo bioluminescent imaging (BLI)</title>
<p>SAS/<italic>luc</italic> tumor-bearing mice received 150 mg/kg D-luciferin injection intraperitoneally. Before imaging, mice were anesthetized using 1&#x02013;3&#x00025; isoflurane for 15 min and continuously exposed to 1&#x02013;2&#x00025; isoflurane to maintain a sedative state during imaging. The photons emitted from the tumors were detected <italic>in vivo</italic> by IVIS 50 Imaging system (Xenogen Corp., Alameda, CA, USA). Image acquisition time was 10 sec. Regions of interest (ROIs) were drawn around the tumor and quantified as photons/second (p/sec) using Living Image software (Xenogen). <italic>In vivo</italic> BLI was performed once a week for three weeks, and the serial bioluminescent signals were quantified and displayed over time.</p></sec>
<sec>
<title>Ex vivo EMSA</title>
<p>Mice were sacrificed on day 21 of the treatment period, and tumors were removed for nuclear protein extraction by using a nuclear extraction kit. The NF-&#x003BA;B/DNA binding activity was evaluated using LightShift Chemiluminescent EMSA kit.</p></sec>
<sec>
<title>Ex vivo western blotting</title>
<p>Mice were sacrificed on day 21 of the treatment period and tumors were removed for protein extraction using the T-PER kit (Thermo Scientific Pierce Protein Biology Products). Equal amounts of protein (40 &#x003BC;g) were loaded on SDS-PAGE for electrophoresis and then transferred to nitrocellulose membranes. The membranes were incubated with primary antibodies specific for VEGF, MMP-9, BCL-2, XIAP, C-FLIP, cleaved caspase-3, caspase-8, cytochrome <italic>c</italic> and &#x003B2;-actin, followed by incubation with horseradish peroxidase-conjugated secondary antibodies. Protein expression was determined by ECL. All reagents and antibodies were purchased from EMD Millipore, except XIAP, which was purchased from Abcam (Cambridge, UK).</p></sec>
<sec>
<title>Statistical analysis</title>
<p>Data are presented as means &#x000B1; standard deviation (SD). Student&#x02019;s t-test was used for analysis, and P&lt;0.05 was considered to indicate a statistically significant result.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Curcumin induces apoptosis and suppresses NF-&#x003BA;B-mediated tumor progression-related proteins in SAS/luc cells in a time-dependent manner</title>
<p><xref rid="f1-or-31-04-1729" ref-type="fig">Fig. 1A</xref> shows that curcumin killed more SAS/<italic>luc</italic> cells, as depicted by decreased cell viability, with increasing concentrations (10&#x02013;50 &#x003BC;M) and longer treatment time (48 h). The IC<sub>50</sub> for curcumin was about 30 &#x003BC;M, which was selected for subsequent experiments. DNA laddering, which represents cell apoptosis, became more obvious in the SAS/<italic>luc</italic> cells when the cells were treated with curcumin for 48 h as compared to that at 24 h (<xref rid="f1-or-31-04-1729" ref-type="fig">Fig. 1B</xref>). Curcumin suppressed NF-&#x003BA;B/DNA binding activity also in a time-dependent manner (<xref rid="f1-or-31-04-1729" ref-type="fig">Fig. 1C</xref>). Expression of apoptotic proteins (i.e. cleaved caspase-3, cleaved caspase-8 and cytochrome <italic>c</italic>) increased while NF-&#x003BA;B-regulated effector proteins (i.e. angiogenesis protein VEGF, invasion protein MMP-9 and anti-apoptosis proteins BCL-2, XIAP and C-FLIP) decreased with curcumin treatment (<xref rid="f1-or-31-04-1729" ref-type="fig">Fig. 1D</xref>), both in a time-dependent manner.</p></sec>
<sec>
<title>Transfection of p-I&#x003BA;B&#x003B1;M suppresses radiation-induced NF-&#x003BA;B activity and sensitizes SAS/luc cells to radiation</title>
<p>SAS cells were transfected with p-I&#x003BA;B&#x003B1;M, a super-repressor of NF-&#x003BA;B, as a negative control of NF-&#x003BA;B activation. The radiation-induced NF-&#x003BA;B/DNA binding activity was inhibited by p-I&#x003BA;B&#x003B1;M (<xref rid="f2-or-31-04-1729" ref-type="fig">Fig. 2A</xref>). Transfection of p-I&#x003BA;B&#x003B1;M significantly increased radiation cytotoxicity at all doses (2&#x02013;12 Gy) as compared with the transfection of the empty vector (<xref rid="f2-or-31-04-1729" ref-type="fig">Fig. 2B</xref>). Radiation-induced apoptosis, represented by DNA fragmentation (<xref rid="f2-or-31-04-1729" ref-type="fig">Fig. 2C</xref>) or increased apoptosis-related protein levels (<xref rid="f2-or-31-04-1729" ref-type="fig">Fig. 2D</xref>), was also enhanced following the transfection of p-I&#x003BA;B&#x003B1;M. Finally, the expression of radiation-induced NF-&#x003BA;B downstream effector proteins (i.e. VEGF, MMP-9, BCL-2, XIAP and C-FLIP) was inhibited by the transfection of p-I&#x003BA;B&#x003B1;M (<xref rid="f2-or-31-04-1729" ref-type="fig">Fig. 2D</xref>).</p></sec>
<sec>
<title>Curcumin suppresses radiation-induced NF-&#x003BA;B activity and synergistically sensitizes SAS/luc cells to radiation</title>
<p>Curcumin inhibited radiation-induced NF-&#x003BA;B/DNA binding activity (<xref rid="f3-or-31-04-1729" ref-type="fig">Fig. 3A</xref>). The combination of curcumin with radiation significantly decreased the survival fraction at all doses (2&#x02013;12 Gy) when compared with the radiation alone group (<xref rid="f3-or-31-04-1729" ref-type="fig">Fig. 3B</xref>). Synergistic effects were noticed with radiation doses &gt;2 Gy (<xref rid="tI-or-31-04-1729" ref-type="table">Table I</xref>). In addition, curcumin increased radiation-induced apoptosis as shown by DNA fragmentation (<xref rid="f3-or-31-04-1729" ref-type="fig">Fig. 3C</xref>) and increased apoptotic proteins levels (i.e. cleaved caspase-3, cleaved caspase-8 and cytochrome <italic>c</italic> in <xref rid="f3-or-31-04-1729" ref-type="fig">Fig. 3D</xref>). <xref rid="f3-or-31-04-1729" ref-type="fig">Fig. 3D</xref> indicates that curcumin suppressed radiation-induced NF-&#x003BA;B downstream effector protein expression (i.e. VEGF, MMP-9, BCL-2, XIAP and C-FLIP). These findings were identical to those observed in the aforementioned p-I&#x003BA;B&#x003B1;M-transfected group.</p></sec>
<sec>
<title>Curcumin enhances the therapeutic efficacy of radiation in the SAS/luc tumor-bearing mice</title>
<p><xref rid="f4-or-31-04-1729" ref-type="fig">Fig. 4</xref> depicts a flow chart of the <italic>in vivo</italic> experiment. SAS/<italic>luc</italic> tumor-bearing mice were divided into four groups: the vehicle-treated control (vehicle) group, the curcumin-treated (curcumin alone) group, the radiation-treated (radiation alone) group, and the combined treatment (combination) group. Mice were treated according to the grouping when the tumor volume reached 70 mm<sup>3</sup>. <xref rid="f5-or-31-04-1729" ref-type="fig">Fig. 5A</xref> depicts the tumor growth curve measured by caliper during the experiment. All the treatment groups showed significantly enhanced inhibition of tumor growth when compared with the control group. The combined treatment group (combination) exhibited optimal tumor control and a significantly smaller tumor volume on day 21 in comparison with the curcumin-treated (curcumin alone) or radiation-treated (radiation alone) group. BLI was also used to evaluate the therapeutic efficacy. On day 21 as shown in <xref rid="f5-or-31-04-1729" ref-type="fig">Fig. 5B and C</xref>, photons emitted from the tumors of the treatment groups were significantly lower than photons from the tumors of the control group. Photon flux of the combination group was significantly lower when compared with the photon flux in the curcumin or radiation alone group. As predicted in the <italic>in vitro</italic> data, <italic>ex vivo</italic> EMSA and western blotting showed that curcumin inhibited radiation-induced NF-&#x003BA;B/DNA binding activity, increased radiation-induced apoptotic protein levels, and suppressed radiation-induced NF-&#x003BA;B downstream effector protein expression (<xref rid="f5-or-31-04-1729" ref-type="fig">Fig. 5D and E</xref>). We traced body weight changes of the mice to evaluate the potential toxicity caused by the treatments. There were no significant changes (i.e. within 20&#x00025; of the original weight) observed in all four groups (<xref rid="f6-or-31-04-1729" ref-type="fig">Fig. 6A</xref>). Pathological examination showed no difference in the mouse liver morphology among all the groups (<xref rid="f6-or-31-04-1729" ref-type="fig">Fig. 6B</xref>).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Radiotherapy- or chemotherapy-induced NF-&#x003BA;B activity has been reported in numerous studies and is closely correlated with radioresistance or chemoresistance (<xref rid="b5-or-31-04-1729" ref-type="bibr">5</xref>). Inappropriate NF-&#x003BA;B activation results in malignant behavior and antiapoptotic activity of OSCC (<xref rid="b24-or-31-04-1729" ref-type="bibr">24</xref>,<xref rid="b25-or-31-04-1729" ref-type="bibr">25</xref>). In clinical practice, it was found that overexpression of NF-&#x003BA;B is highly correlated with poor treatment outcome (<xref rid="b26-or-31-04-1729" ref-type="bibr">26</xref>). We previously showed that curcumin inhibits the proliferation of human OSCC both <italic>in vitro</italic> and <italic>in vivo</italic> by inducing apoptosis (<xref rid="b18-or-31-04-1729" ref-type="bibr">18</xref>). However, inhibition of NF-&#x003BA;B activation does not always result in enhanced radiosensitivity. Instead, radiosensitization is a cell type-specific phenomenon following NF-&#x003BA;B suppression (<xref rid="b27-or-31-04-1729" ref-type="bibr">27</xref>). The transfection of p-I&#x003BA;B&#x003B1;M, a super repressor of NF-&#x003BA;B, inhibits 12-<italic>O</italic>-tetradecanoylphorbol-13-acetate (TPA)-induced NF-&#x003BA;B activity (<xref rid="b19-or-31-04-1729" ref-type="bibr">19</xref>) and increases radiation-induced cytotoxicity in breast cancer (<xref rid="b28-or-31-04-1729" ref-type="bibr">28</xref>). We found that the radiation-induced NF-&#x003BA;B/DNA binding activity and NF-&#x003BA;B-regulated effector protein expression were inhibited by p-I&#x003BA;B&#x003B1;M (<xref rid="f2-or-31-04-1729" ref-type="fig">Fig. 2A and D</xref>). In addition, p-I&#x003BA;B&#x003B1;M enhanced radiation-induced cytotoxicity and apoptosis via the mitochondrial-dependent and -independent pathways as shown in <xref rid="f2-or-31-04-1729" ref-type="fig">Fig. 2B&#x02013;D</xref>. These results together suggest that inhibition of radiation-induced NF-&#x003BA;B activity is able to sensitize SAS cells to radiation (<xref rid="f2-or-31-04-1729" ref-type="fig">Fig. 2</xref>).</p>
<p>Several methods have been suggested to suppress NF-&#x003BA;B activation and various synthetic drugs or natural compounds are used to inhibit radiation-induced NF-&#x003BA;B activity (<xref rid="b29-or-31-04-1729" ref-type="bibr">29</xref>,<xref rid="b30-or-31-04-1729" ref-type="bibr">30</xref>). Natural compounds are preferred in clinical practice due to low cytotoxicity and multiple mechanisms of action (<xref rid="b14-or-31-04-1729" ref-type="bibr">14</xref>,<xref rid="b31-or-31-04-1729" ref-type="bibr">31</xref>). Curcumin is a natural compound capable of decreasing cell survival, invasion, and angiogenesis via NF-&#x003BA;B signal cascade suppression in several types of cancers (<xref rid="b31-or-31-04-1729" ref-type="bibr">31</xref>,<xref rid="b32-or-31-04-1729" ref-type="bibr">32</xref>). Our experimental results on the OSCC cell line SAS/<italic>luc</italic> showed that curcumin inhibited cell proliferation (<xref rid="f1-or-31-04-1729" ref-type="fig">Fig. 1A</xref>), constitutive NF-&#x003BA;B/DNA binding activity (<xref rid="f1-or-31-04-1729" ref-type="fig">Fig. 1C</xref>) and NF-&#x003BA;B downstream effector protein expression (<xref rid="f1-or-31-04-1729" ref-type="fig">Fig. 1D</xref>) while it induced apoptosis via the mitochondrial-dependent and -independent pathways (<xref rid="f1-or-31-04-1729" ref-type="fig">Fig. 1B and D</xref>). Furthermore, curcumin inhibited radiation-induced NF-&#x003BA;B/DNA binding activity (<xref rid="f3-or-31-04-1729" ref-type="fig">Fig. 3A</xref>) and NF-&#x003BA;B-regulated effector protein expression (<xref rid="f3-or-31-04-1729" ref-type="fig">Fig. 3D</xref>) in addition to enhancing radiation cytotoxicity (<xref rid="f3-or-31-04-1729" ref-type="fig">Fig. 3B</xref>) and apoptosis (<xref rid="f3-or-31-04-1729" ref-type="fig">Fig. 3C and D</xref>). When compared with the surviving fraction of the radiation alone group, the combination group showed the synergistic effect (<xref rid="tI-or-31-04-1729" ref-type="table">Table I</xref>) of curcumin. All these findings indicate that curcumin sensitizes SAS cells to radiation <italic>in vitro</italic>, similar to that observed in p-I&#x003BA;B&#x003B1;M-transfected cells, via inhibition of radiation-induced NF-&#x003BA;B activity.</p>
<p><xref rid="f5-or-31-04-1729" ref-type="fig">Fig. 5A&#x02013;C</xref> shows that curcumin enhanced the antitumor effect of radiation in SAS/<italic>luc</italic> cells <italic>in vivo</italic> through suppression of radiation-induced NF-&#x003BA;B/DNA binding activity (<xref rid="f5-or-31-04-1729" ref-type="fig">Fig. 5D</xref>) and NF-&#x003BA;B-regulated effector protein expression (<xref rid="f5-or-31-04-1729" ref-type="fig">Fig. 5E</xref>). The body weight changes of all the mice throughout the entire experiment were within 20&#x00025; of the original weight (<xref rid="f6-or-31-04-1729" ref-type="fig">Fig. 6A</xref>). In addition, no evidence of liver parenchymal injury or morphologic change was found by pathological examination. Both results indicated that there was no marked toxicity of curcumin treatment. No toxicity has been reported for curcumin at a single dose of 12 g/day by oral administration in a clinical trial (<xref rid="b33-or-31-04-1729" ref-type="bibr">33</xref>). Thus, curcumin may be an ideal radiosensitizer for future clinical use because of its radiosensitizing effect and extremely low toxicity.</p>
<p>In conclusion, the present study demonstrated that curcumin sensitizes human OSCC to radiation via inhibition of radiation-induced NF-&#x003BA;B activity. Combination of curcumin with radiation exerts a synergistic effect <italic>in vitro</italic> and enhances tumor control <italic>in vivo</italic> without noticeable toxicity.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The present study was supported by grants NSC 97-2314-B-010-045-MY3 and NSC 97-2314-B-010-046-MY3 from the National Science Council, Taipei, Taiwan. The imaging facility was supported by the Taiwan Mouse Clinic.</p></ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="G1">BCL-2</term>
<def>
<p>B-cell lymphoma 2 protein</p></def></def-item>
<def-item>
<term id="G2">BLI</term>
<def>
<p>bioluminescence imaging</p></def></def-item>
<def-item>
<term id="G3">CCRT</term>
<def>
<p>combined chemotherapy and radiotherapy</p></def></def-item>
<def-item>
<term id="G4">C-FLIP</term>
<def>
<p>cellular FLICE-like inhibitory protein</p></def></def-item>
<def-item>
<term id="G5">COX-2</term>
<def>
<p>cyclooxygenase-2</p></def></def-item>
<def-item>
<term id="G6">DMEM</term>
<def>
<p>Dulbecco&#x02019;s modified essential medium</p></def></def-item>
<def-item>
<term id="G7">ECL</term>
<def>
<p>enhanced chemiluminescence</p></def></def-item>
<def-item>
<term id="G8">EGFR</term>
<def>
<p>epidermal growth factor receptor</p></def></def-item>
<def-item>
<term id="G9">ELISA</term>
<def>
<p>enzyme-linked immunosorbent assay</p></def></def-item>
<def-item>
<term id="G10">EMSA</term>
<def>
<p>electrophoretic mobility shift assay</p></def></def-item>
<def-item>
<term id="G11">HIF-&#x003B1;</term>
<def>
<p>hypoxia-inducible factor-&#x003B1;</p></def></def-item>
<def-item>
<term id="G12"><italic>luc</italic></term>
<def>
<p>luciferase gene</p></def></def-item>
<def-item>
<term id="G13">MTT</term>
<def>
<p>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></def></def-item>
<def-item>
<term id="G14">MMP-9</term>
<def>
<p>matrix metalloproteinase-9</p></def></def-item>
<def-item>
<term id="G15">NF-&#x003BA;B</term>
<def>
<p>nuclear factor-&#x003BA;B</p></def></def-item>
<def-item>
<term id="G16">OSCC</term>
<def>
<p>oral squamous cell carcinoma</p></def></def-item>
<def-item>
<term id="G17">p-I&#x003BA;B&#x003B1;M</term>
<def>
<p>NF-&#x003BA;B super-repressor</p></def></def-item>
<def-item>
<term id="G18">SDS-PAGE</term>
<def>
<p>sodium dodecyl sulfate polyacrylamide gel electrophoresis</p></def></def-item>
<def-item>
<term id="G19">SF</term>
<def>
<p>surviving fraction</p></def></def-item>
<def-item>
<term id="G20">SSD</term>
<def>
<p>source-to-skin distance</p></def></def-item>
<def-item>
<term id="G21">TNF-&#x003B1;</term>
<def>
<p>tumor necrosis factor-&#x003B1;</p></def></def-item>
<def-item>
<term id="G22">TPA</term>
<def>
<p>12-<italic>O</italic>-tetradecanoylphorbol-13-acetate</p></def></def-item>
<def-item>
<term id="G23">VEGF</term>
<def>
<p>vascular endothelial growth factor</p></def></def-item>
<def-item>
<term id="G24">XIAP</term>
<def>
<p>x-linked inhibitor of apoptosis protein</p></def></def-item></def-list></glossary>
<ref-list>
<title>References</title>
<ref id="b1-or-31-04-1729"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>JN</given-names></name><name><surname>Greenberg</surname><given-names>JS</given-names></name><name><surname>Mo</surname><given-names>V</given-names></name><name><surname>Roberts</surname><given-names>D</given-names></name></person-group><article-title>Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue</article-title><source>Cancer</source><volume>92</volume><fpage>3030</fpage><lpage>3036</lpage><year>2001</year></element-citation></ref>
<ref id="b2-or-31-04-1729"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunnumakkara</surname><given-names>AB</given-names></name><name><surname>Diagaradjane</surname><given-names>P</given-names></name><name><surname>Guha</surname><given-names>S</given-names></name><etal/></person-group><article-title>Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-&#x003BA;B-regulated gene products</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>2128</fpage><lpage>2136</lpage><year>2008</year></element-citation></ref>
<ref id="b3-or-31-04-1729"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunigal</surname><given-names>S</given-names></name><name><surname>Lakka</surname><given-names>SS</given-names></name><name><surname>Joseph</surname><given-names>P</given-names></name><name><surname>Estes</surname><given-names>N</given-names></name><name><surname>Rao</surname><given-names>JS</given-names></name></person-group><article-title>Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-&#x003BA;B activity leading to apoptosis in breast tumors</article-title><source>Clin Cancer Res</source><volume>14</volume><fpage>3617</fpage><lpage>3626</lpage><year>2008</year></element-citation></ref>
<ref id="b4-or-31-04-1729"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veeraraghavan</surname><given-names>J</given-names></name><name><surname>Natarajan</surname><given-names>M</given-names></name><name><surname>Aravindan</surname><given-names>S</given-names></name><name><surname>Herman</surname><given-names>TS</given-names></name><name><surname>Aravindan</surname><given-names>N</given-names></name></person-group><article-title>Radiation-triggered tumor necrosis factor (TNF) &#x003B1;-NF&#x003BA;B cross-signaling favors survival advantage in human neuroblastoma cells</article-title><source>J Biol Chem</source><volume>286</volume><fpage>21588</fpage><lpage>21600</lpage><year>2011</year></element-citation></ref>
<ref id="b5-or-31-04-1729"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name></person-group><article-title>Targeting transcription factor NF-&#x003BA;B to overcome chemoresistance and radioresistance in cancer therapy</article-title><source>Biochim Biophys Acta</source><volume>1805</volume><fpage>167</fpage><lpage>180</lpage><year>2010</year></element-citation></ref>
<ref id="b6-or-31-04-1729"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>CT</given-names></name><name><surname>Ricker</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Van Waes</surname><given-names>C</given-names></name></person-group><article-title>Role of activated nuclear factor-&#x003BA;B in the pathogenesis and therapy of squamous cell carcinoma of the head and neck</article-title><source>Head Neck</source><volume>29</volume><fpage>959</fpage><lpage>971</lpage><year>2007</year></element-citation></ref>
<ref id="b7-or-31-04-1729"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bancroft</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>G</given-names></name><etal/></person-group><article-title>Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-&#x003BA;B signal pathways</article-title><source>Clin Cancer Res</source><volume>7</volume><fpage>435</fpage><lpage>442</lpage><year>2001</year></element-citation></ref>
<ref id="b8-or-31-04-1729"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henriques</surname><given-names>AC</given-names></name><name><surname>de Matos</surname><given-names>FR</given-names></name><name><surname>Galvao</surname><given-names>HC</given-names></name><name><surname>Freitas Rde</surname><given-names>A</given-names></name></person-group><article-title>Immunohistochemical expression of MMP-9 and VEGF in squamous cell carcinoma of the tongue</article-title><source>J Oral Sci</source><volume>54</volume><fpage>105</fpage><lpage>111</lpage><year>2012</year></element-citation></ref>
<ref id="b9-or-31-04-1729"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahmani</surname><given-names>A</given-names></name><name><surname>Alzohairy</surname><given-names>M</given-names></name><name><surname>Babiker</surname><given-names>AY</given-names></name><name><surname>Rizvi</surname><given-names>MA</given-names></name><name><surname>Elkarimahmad</surname><given-names>HG</given-names></name></person-group><article-title>Clinicopathological significance of PTEN and bcl2 expressions in oral squamous cell carcinoma</article-title><source>Int J Clin Exp Pathol</source><volume>5</volume><fpage>965</fpage><lpage>971</lpage><year>2012</year></element-citation></ref>
<ref id="b10-or-31-04-1729"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagi</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>GQ</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Genden</surname><given-names>E</given-names></name><name><surname>Burstein</surname><given-names>DE</given-names></name></person-group><article-title>Immunohistochemical detection of X-linked inhibitor of apoptosis in head and neck squamous cell carcinoma</article-title><source>Ann Diagn Pathol</source><volume>11</volume><fpage>402</fpage><lpage>406</lpage><year>2007</year></element-citation></ref>
<ref id="b11-or-31-04-1729"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentires-Alj</surname><given-names>M</given-names></name><name><surname>Barbu</surname><given-names>V</given-names></name><name><surname>Fillet</surname><given-names>M</given-names></name><etal/></person-group><article-title>NF-&#x003BA;B transcription factor induces drug resistance through MDR1 expression in cancer cells</article-title><source>Oncogene</source><volume>22</volume><fpage>90</fpage><lpage>97</lpage><year>2003</year></element-citation></ref>
<ref id="b12-or-31-04-1729"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>YC</given-names></name><name><surname>Lin</surname><given-names>WC</given-names></name><name><surname>Chiang</surname><given-names>IT</given-names></name><etal/></person-group><article-title>Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-&#x003BA;B expression in vitro and in vivo</article-title><source>Biomed Pharmacother</source><volume>66</volume><fpage>12</fpage><lpage>20</lpage><year>2012</year></element-citation></ref>
<ref id="b13-or-31-04-1729"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>JS</given-names></name><name><surname>Pajak</surname><given-names>TF</given-names></name><name><surname>Forastiere</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck</article-title><source>N Engl J Med</source><volume>350</volume><fpage>1937</fpage><lpage>1944</lpage><year>2004</year></element-citation></ref>
<ref id="b14-or-31-04-1729"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Kunnumakkara</surname><given-names>AB</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Curcumin as &#x02018;Curecumin&#x02019;: from kitchen to clinic</article-title><source>Biochem Pharmacol</source><volume>75</volume><fpage>787</fpage><lpage>809</lpage><year>2008</year></element-citation></ref>
<ref id="b15-or-31-04-1729"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>HS</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><etal/></person-group><article-title>A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiation</article-title><source>Int J Nanomed</source><volume>7</volume><fpage>2601</fpage><lpage>2611</lpage><year>2012</year></element-citation></ref>
<ref id="b16-or-31-04-1729"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LoTempio</surname><given-names>MM</given-names></name><name><surname>Veena</surname><given-names>MS</given-names></name><name><surname>Steele</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Curcumin suppresses growth of head and neck squamous cell carcinoma</article-title><source>Clin Cancer Res</source><volume>11</volume><fpage>6994</fpage><lpage>7002</lpage><year>2005</year></element-citation></ref>
<ref id="b17-or-31-04-1729"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khafif</surname><given-names>A</given-names></name><name><surname>Lev-Ari</surname><given-names>S</given-names></name><name><surname>Vexler</surname><given-names>A</given-names></name><etal/></person-group><article-title>Curcumin: a potential radio-enhancer in head and neck cancer</article-title><source>Laryngoscope</source><volume>119</volume><fpage>2019</fpage><lpage>2026</lpage><year>2009</year></element-citation></ref>
<ref id="b18-or-31-04-1729"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Kuo</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>YF</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Hwang</surname><given-names>JJ</given-names></name></person-group><article-title>Therapeutic efficacy evaluation of curcumin on human oral squamous cell carcinoma xenograft using multimodalities of molecular imaging</article-title><source>Am J Chin Med</source><volume>38</volume><fpage>343</fpage><lpage>358</lpage><year>2010</year></element-citation></ref>
<ref id="b19-or-31-04-1729"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>IT</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-&#x003BA;B pathway in hepatocellular carcinoma cells</article-title><source>In Vivo</source><volume>26</volume><fpage>671</fpage><lpage>681</lpage><year>2012</year></element-citation></ref>
<ref id="b20-or-31-04-1729"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valeriote</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name></person-group><article-title>Synergistic interaction of anticancer agents: a cellular perspective</article-title><source>Cancer Chemother Rep</source><volume>59</volume><fpage>895</fpage><lpage>900</lpage><year>1975</year></element-citation></ref>
<ref id="b21-or-31-04-1729"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpentier</surname><given-names>Y</given-names></name><name><surname>Demange</surname><given-names>L</given-names></name><name><surname>Loirette</surname><given-names>M</given-names></name><name><surname>Hivet</surname><given-names>J</given-names></name><name><surname>Desoize</surname><given-names>B</given-names></name></person-group><article-title>Chronology of combined chemotherapy (5FU) and radiotherapy. I In vitro study</article-title><source>Anticancer Res</source><volume>13</volume><fpage>2177</fpage><lpage>2180</lpage><year>1993</year></element-citation></ref>
<ref id="b22-or-31-04-1729"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WH</given-names></name><name><surname>Chiang</surname><given-names>IT</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name><etal/></person-group><article-title>Curcumin-induced apoptosis in human hepatocellular carcinoma J5 cells: critical role of Ca<sup>2&#x0002B;</sup>-dependent pathway</article-title><source>Evid Based Complement Alternat Med</source><volume>2012</volume><fpage>512907</fpage><year>2012</year></element-citation></ref>
<ref id="b23-or-31-04-1729"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgos</surname><given-names>JS</given-names></name><name><surname>Rosol</surname><given-names>M</given-names></name><name><surname>Moats</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice</article-title><source>Biotechniques</source><volume>34</volume><fpage>1184</fpage><lpage>1188</lpage><year>2003</year></element-citation></ref>
<ref id="b24-or-31-04-1729"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>H</given-names></name><name><surname>Ikebe</surname><given-names>T</given-names></name><name><surname>Beppu</surname><given-names>M</given-names></name><name><surname>Shirasuna</surname><given-names>K</given-names></name></person-group><article-title>High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity</article-title><source>Cancer</source><volume>92</volume><fpage>3037</fpage><lpage>3044</lpage><year>2001</year></element-citation></ref>
<ref id="b25-or-31-04-1729"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindhu</surname><given-names>OS</given-names></name><name><surname>Ramadas</surname><given-names>K</given-names></name><name><surname>Sebastian</surname><given-names>P</given-names></name><name><surname>Pillai</surname><given-names>MR</given-names></name></person-group><article-title>High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma</article-title><source>Head Neck</source><volume>28</volume><fpage>916</fpage><lpage>925</lpage><year>2006</year></element-citation></ref>
<ref id="b26-or-31-04-1729"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>R</given-names></name><name><surname>Nishimura</surname><given-names>H</given-names></name><etal/></person-group><article-title>Nuclear factor-&#x003BA;B expression as a novel marker of radioresistance in early-stage laryngeal cancer</article-title><source>Head Neck</source><volume>32</volume><fpage>646</fpage><lpage>655</lpage><year>2010</year></element-citation></ref>
<ref id="b27-or-31-04-1729"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>KM</given-names></name><name><surname>Li</surname><given-names>JJ</given-names></name></person-group><article-title>NF-&#x003BA;B-mediated adaptive resistance to ionizing radiation</article-title><source>Free Radic Biol Med</source><volume>44</volume><fpage>1</fpage><lpage>13</lpage><year>2008</year></element-citation></ref>
<ref id="b28-or-31-04-1729"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>YC</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Co-activation of ERK, NF-&#x003BA;B, and GADD<sub>45</sub>&#x003B2; in response to ionizing radiation</article-title><source>J Biol Chem</source><volume>280</volume><fpage>12593</fpage><lpage>12601</lpage><year>2005</year></element-citation></ref>
<ref id="b29-or-31-04-1729"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>St Clair</surname><given-names>DK</given-names></name><name><surname>Sompol</surname><given-names>P</given-names></name><name><surname>Josson</surname><given-names>S</given-names></name><name><surname>St Clair</surname><given-names>WH</given-names></name></person-group><article-title>SN52, a novel nuclear factor-&#x003BA;B inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation</article-title><source>Mol Cancer Ther</source><volume>7</volume><fpage>2367</fpage><lpage>2376</lpage><year>2008</year></element-citation></ref>
<ref id="b30-or-31-04-1729"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>GZ</given-names></name><name><surname>Oh</surname><given-names>ET</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>MT</given-names></name><name><surname>Song</surname><given-names>CW</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name></person-group><article-title>&#x003B2;-lapachone suppresses radiation-induced activation of nuclear factor-&#x003BA;B</article-title><source>Exp Mol Med</source><volume>42</volume><fpage>327</fpage><lpage>334</lpage><year>2010</year></element-citation></ref>
<ref id="b31-or-31-04-1729"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunnumakkara</surname><given-names>AB</given-names></name><name><surname>Anand</surname><given-names>P</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins</article-title><source>Cancer Lett</source><volume>269</volume><fpage>199</fpage><lpage>225</lpage><year>2008</year></element-citation></ref>
<ref id="b32-or-31-04-1729"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chendil</surname><given-names>D</given-names></name><name><surname>Ranga</surname><given-names>RS</given-names></name><name><surname>Meigooni</surname><given-names>D</given-names></name><name><surname>Sathishkumar</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>MM</given-names></name></person-group><article-title>Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3</article-title><source>Oncogene</source><volume>23</volume><fpage>1599</fpage><lpage>1607</lpage><year>2004</year></element-citation></ref>
<ref id="b33-or-31-04-1729"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lao</surname><given-names>CD</given-names></name><name><surname>Ruffin</surname><given-names>MT</given-names><suffix>IV</suffix></name><name><surname>Normolle</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dose escalation of a curcuminoid formulation</article-title><source>BMC Complement Altern Med</source><volume>6</volume><fpage>10</fpage><year>2006</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-or-31-04-1729" position="float">
<label>Figure 1</label>
<caption>
<p>Curcumin inhibits tumor progression of SAS/<italic>luc</italic> cells in a time-dependent manner. (A) The SAS/<italic>luc</italic> cells were treated with 0&#x02013;50 &#x003BC;M curcumin for 24 or 48 h. The cell viability was evaluated using an MTT assay. (B) Curcumin induced DNA fragmentation. (C) The result of EMSA indicated that the NF-&#x003BA;B/DNA binding activity was suppressed by curcumin. (D) Western blotting revealed changes in the level of apoptotic-related and NF-&#x003BA;B-regulated proteins after curcumin treatment. &#x003B2;-actin was used as an internal control. Representative data from three independent experiments are shown. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01.</p></caption>
<graphic xlink:href="OR-31-04-1729-g00.gif"/></fig>
<fig id="f2-or-31-04-1729" position="float">
<label>Figure 2</label>
<caption>
<p>Transfection of p-I&#x003BA;B&#x003B1;M sensitizes SAS cells to radiation. (A) Transfection of p-I&#x003BA;B&#x003B1;M inhibited radiation-induced NF-&#x003BA;B activity. The NF-&#x003BA;B/DNA binding activity was evaluated with EMSA. (B) Transfection of p-I&#x003BA;B&#x003B1;M significantly increased radiation-induced cytotoxicity. The surviving fraction was determined with a clonogenic survival assay. (C) Transfection of p-I&#x003BA;B&#x003B1;M increased radiation-induced DNA fragmentation. (D) Transfection of p-I&#x003BA;B&#x003B1;M decreased radiation-induced NF-&#x003BA;B-regulated protein expression and increased radiation-induced apoptosis-related protein expression. Protein expression was assayed by western blotting. Representative data from three independent experiments are shown. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 as compared with the empty vector. Ctr, empty vector; I&#x003BA;B&#x003B1;M, I&#x003BA;B&#x003B1;M vector; R, radiation alone; Comb, combination.</p></caption>
<graphic xlink:href="OR-31-04-1729-g01.gif"/></fig>
<fig id="f3-or-31-04-1729" position="float">
<label>Figure 3</label>
<caption>
<p>Curcumin sensitizes SAS/<italic>luc</italic> cells to radiation. (A) Radiation-induced NF-&#x003BA;B activity was inhibited by curcumin treatment. The NF-&#x003BA;B/DNA binding activity was evaluated with EMSA. (B) Curcumin significantly increased radiation-induced cytotoxicity. SAS/<italic>luc</italic> cells were treated with or without 30 &#x003BC;M curcumin followed by immediate irradiation with various doses (see context for detail). The surviving fraction was determined with clonogenic survival assay. (C) Curcumin increased radiation-induced DNA fragmentation. (D) Curcumin decreased radiation-induced NF-&#x003BA;B-regulated protein expression and increased radiation-induced apoptosis-related protein expression. Protein expression was assayed by western blotting. (Representative data from three independent experiments are shown. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 as compared with radiation alone. Ctr, control; Cur, curcumin alone; R, radiation alone; Comb, combination.</p></caption>
<graphic xlink:href="OR-31-04-1729-g02.gif"/></fig>
<fig id="f4-or-31-04-1729" position="float">
<label>Figure 4</label>
<caption>
<p>Schematic depiction of the experimental design. SAS/<italic>luc</italic> tumor-bearing mice were divided into four groups: vehicle-treated control group; radiation-treated (single 6 Gy on day 1) group; curcumin-treated (70 mg/kg/day by gavage from day 1) group; and combined treatment (curcumin plus radiation) group.</p></caption>
<graphic xlink:href="OR-31-04-1729-g03.gif"/></fig>
<fig id="f5-or-31-04-1729" position="float">
<label>Figure 5</label>
<caption>
<p>Curcumin sensitizes SAS/<italic>luc</italic> tumor-bearing mice to radiation. (A) The combined treatment group (combination) exhibited significantly inhibited tumor growth when compared with the other groups. (B) The therapeutic efficacy in SAS/<italic>luc</italic> tumor-bearing mice was evaluated with bioluminescent imaging (BLI). (C) The photon flux of BLI was quantified, and the value was the lowest in the combination group when compared with the other groups. (D) Curcumin inhibited radiation-induced NF-&#x003BA;B activation in the SAS/<italic>luc</italic> tumor tissues. The NF-&#x003BA;B activation of tumors in mice was determined using <italic>ex vivo</italic> EMSA. (E) <italic>Ex vivo</italic> western blotting demonstrated that curcumin decreased radiation-induced NF-&#x003BA;B-regulated effector protein expression and increased radiation-induced apoptotic protein expression in the SAS/<italic>luc</italic> tumor tissues (n&#x0003D;5 in each group). Representative data from three independent experiments are shown. <sup>&#x0002A;</sup>P&lt;0.05, <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 as compared with the control. <sup>&#x00023;</sup>P&lt;0.05, <sup>&#x00023;&#x00023;</sup>P&lt;0.01 as compared with the other treatment groups.</p></caption>
<graphic xlink:href="OR-31-04-1729-g04.gif"/></fig>
<fig id="f6-or-31-04-1729" position="float">
<label>Figure 6</label>
<caption>
<p>Low toxicity of curcumin treatment. (A) No significant body weight changes were noted in all groups. This result indicates that curcumin plus radiation was well tolerated by the mice. (B) Pathological examination with H&amp;E staining showed no liver parenchymal change in all groups.</p></caption>
<graphic xlink:href="OR-31-04-1729-g05.gif"/></fig>
<table-wrap id="tI-or-31-04-1729" position="float">
<label>Table I</label>
<caption>
<p>Effect of 30 &#x003BC;M curcumin combined with various doses of radiation on SAS/<italic>luc</italic> cells.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Radiation (Gy)</th>
<th align="center" valign="bottom">SF<sub>R</sub></th>
<th align="center" valign="bottom">SF<sub>R&#x0002B;C</sub></th>
<th align="center" valign="bottom">SF<sub>R</sub> &#x000D7; SF<sub>C</sub></th></tr></thead>
<tbody>
<tr>
<td align="right" valign="top">2</td>
<td align="center" valign="top">0.56</td>
<td align="left" valign="top">0.37 (sub-additivity)</td>
<td align="center" valign="top">0.28</td></tr>
<tr>
<td align="right" valign="top">4</td>
<td align="center" valign="top">0.42</td>
<td align="left" valign="top">0.13 (synergism)</td>
<td align="center" valign="top">0.21</td></tr>
<tr>
<td align="right" valign="top">6</td>
<td align="center" valign="top">0.22</td>
<td align="left" valign="top">0.05 (synergism)</td>
<td align="center" valign="top">0.11</td></tr>
<tr>
<td align="right" valign="top">8</td>
<td align="center" valign="top">0.08</td>
<td align="left" valign="top">0.01 (synergism)</td>
<td align="center" valign="top">0.04</td></tr>
<tr>
<td align="right" valign="top">10</td>
<td align="center" valign="top">0.03</td>
<td align="left" valign="top">0.003 (synergism)</td>
<td align="center" valign="top">0.01</td></tr>
<tr>
<td align="right" valign="top">12</td>
<td align="center" valign="top">0.01</td>
<td align="left" valign="top">0.0005 (synergism)</td>
<td align="center" valign="top">0.00</td></tr></tbody></table></table-wrap></floats-group></article>
